Stockhead – Dr Boreham’s Crucible: how $18bn snore buster ResMed stacks up against ASX sleep minnows

Small cap share analyst and business journalist, Tim Boreham covers companies operating the sleep treatment space. This Stockhead article includes a section on Oventus’ Sleep Treatment Platform.

To read the article, click here.

Leave a Reply

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>